Written questions by Platt.

What steps his Department is taking to help increase the number of part 2 overseas registration exam places to help increase the number of dentists delivering NHS care.

The General Dental Council (GDC), as the independent regulator of dentists and dental care professionals in the UK, is responsible for overseeing provision of the Overseas Registration Exam (ORE).The GDC shortly expects to be able to announce the outcome of its procurement for a new provider to deliver the ORE from April 2026.Once the new exam provider has been announced, the GDC will meet with me to present its action plan to reduce the waiting list for the ORE, including for those waiting to sit part 2 of the exam. This meeting will take place in the coming weeks. I will continue to meet regularly with the GDC to monitor and review progress as its plan is implemented.

What steps his Department is taking to ensure that delivery of the 10 Year Plan effectively tackles domestic abuse.

The 10-Year Health Plan will transform the healthcare model in England to create a National Health Service that is fit for the future, delivering more integrated health and care, closer to home, with a renewed focus on prevention and neighbourhoods that will address the injustices faced by victims of domestic abuse.We know that those who experience domestic abuse can have worse NHS access, poorer health outcomes, and die younger. The health sector has a vital role to play in preventing, identifying, and responding to violence and abuse, and in providing healthcare to victims.All health care staff are required to complete mandatory safeguarding training, which includes a focus on domestic abuse. This training is being revised and is due to be re-launched in early 2026.In addition, the Government is working to deliver an ambitious strategy to tackle violence against women and girls (VAWG), including domestic abuse. The new VAWG Strategy is being finalised and will be published as soon as possible.

How much funding his Department plans to allocate for research on ME and Chronic Fatigue Syndrome in the next (a) year and (b) five years.

The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including post-acute infection condition such as myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), for which research funding is available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality, rather than designating an amount of funding for a particular condition. Welcoming applications on ME/CFS and other post-acute infection conditions to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.The NIHR Academy offers extensive support for early-career researchers through various fellowships, training awards, and mentoring structures. For instance, through the INSIGHT Programme, they work with universities to fund research masters studentships and to attract students into research. Through Academic Clinical Fellowships, for doctors and dentists, and Predoctoral Academic Fellowships, for other health professionals, the NIHR Academy supports healthcare practitioners in integrating research with clinical practice.Together with the Medical Research Council (MRC), which is part of UK Research and Innovation, we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS final delivery plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including for ME/CFS and long COVID, later this year to stimulate further research in this field.

What steps his Department is taking to (a) encourage research on and (b) support the development of (i) strategic partnerships and (ii) research infrastructure for ME and Chronic Fatigue Syndrome.

The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including post-acute infection condition such as myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), for which research funding is available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality, rather than designating an amount of funding for a particular condition. Welcoming applications on ME/CFS and other post-acute infection conditions to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.The NIHR Academy offers extensive support for early-career researchers through various fellowships, training awards, and mentoring structures. For instance, through the INSIGHT Programme, they work with universities to fund research masters studentships and to attract students into research. Through Academic Clinical Fellowships, for doctors and dentists, and Predoctoral Academic Fellowships, for other health professionals, the NIHR Academy supports healthcare practitioners in integrating research with clinical practice.Together with the Medical Research Council (MRC), which is part of UK Research and Innovation, we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS final delivery plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including for ME/CFS and long COVID, later this year to stimulate further research in this field.

What the core staffing requirements that the new neighbourhood health teams must fulfil are; and whether these staffing requirements will include a dementia specialist nurse.

The Neighbourhood Health Service will bring together teams of professionals closer to people’s homes to work together to provide comprehensive care in the community. We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations, and so they could include dementia specialist nurses. While we will be clear on the outcomes we expect, we will give significant licence to tailor the approach to local need. While the focus on personalised, coordinated care will be consistent, that will mean the service will look different in rural communities, coastal towns, or deprived inner cities. Provision of dementia health care services is the responsibility of local integrated care boards (ICBs). We would expect ICBs to commission services, which may include dementia specialist nurses/admiral nurses, based on local population needs, taking account of the National Institute for Health and Care Excellence (NICE) guidelines. NICE recommends providing people living with dementia with a single named health or social care professional who is responsible for coordinating their care. Under the 10-Year Plan, those living with dementia will benefit from improved care planning and better services.  We will deliver the first ever Modern Service Framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

What specialist dementia support will be available in neighbourhood health centres to support people with dementia in the community following a hospital stay.

The Neighbourhood Health Service will bring together teams of professionals closer to people’s homes to work together to provide comprehensive care in the community. We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations, and so they could include dementia specialist nurses. While we will be clear on the outcomes we expect, we will give significant licence to tailor the approach to local need. While the focus on personalised, coordinated care will be consistent, that will mean the service will look different in rural communities, coastal towns, or deprived inner cities. Provision of dementia health care services is the responsibility of local integrated care boards (ICBs). We would expect ICBs to commission services, which may include dementia specialist nurses/admiral nurses, based on local population needs, taking account of the National Institute for Health and Care Excellence (NICE) guidelines. NICE recommends providing people living with dementia with a single named health or social care professional who is responsible for coordinating their care. Under the 10-Year Plan, those living with dementia will benefit from improved care planning and better services.  We will deliver the first ever Modern Service Framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

If he will make an assessment of the potential merits of working with Integrated Care Boards to ensure that (a) Admiral Nurses and (b) other dementia specialist nurses are included within each new neighbourhood health team.

The Neighbourhood Health Service will bring together teams of professionals closer to people’s homes to work together to provide comprehensive care in the community. We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations, and so they could include dementia specialist nurses. While we will be clear on the outcomes we expect, we will give significant licence to tailor the approach to local need. While the focus on personalised, coordinated care will be consistent, that will mean the service will look different in rural communities, coastal towns, or deprived inner cities. Provision of dementia health care services is the responsibility of local integrated care boards (ICBs). We would expect ICBs to commission services, which may include dementia specialist nurses/admiral nurses, based on local population needs, taking account of the National Institute for Health and Care Excellence (NICE) guidelines. NICE recommends providing people living with dementia with a single named health or social care professional who is responsible for coordinating their care. Under the 10-Year Plan, those living with dementia will benefit from improved care planning and better services.  We will deliver the first ever Modern Service Framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

If he will take steps to introduce a National Services Framework for dementia.

Our health system has struggled to support those with complex needs, including those with dementia. Under the 10 Year Plan, those living with dementia will benefit from improved care planning and better services.We will deliver the first ever Modern Service Framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.The Modern Service Framework for Frailty and Dementia will seek to reduce unwarranted variation and narrow inequality for those living with dementia, and will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.

Whether he has made an assessment of the potential merits of including a national services framework for dementia as part of the NHS 10-year Health Plan.

The 10-Year Health Plan will address the challenges diagnosed by Lord Darzi and will set the vision for what good joined-up care looks like for people with a combination of complex health and care needs, including people living with dementia. We are carefully considering policies, including those that impact people with dementia, with input from the public, patients, health staff, and our partners, as we develop the plan.

What funding his Department provides to the Violence Against Women and Girls Strategy.

Funding for the forthcoming Violence Against Women and Girls Strategy will be confirmed when the strategy is published in the coming months.Health does make an important contribution to tackling violence against women and girls. For example, NHS England spent £52.8 million on the provision of sexual assault and abuse services in 2023/24. Figures for more recent years are not yet available. The Department also funds the ongoing collection of data on female genital mutilation attendances in the National Health Service.

To make an assessment of the capacity to deliver Early Access Programmes for people with motor neurone disease.

Companies may put in place Early Access Programmes (EAPs) to allow early access to new medicines that do not yet have a marketing authorisation. Participation in EAPs is decided at an individual National Health Service trust level and under these programmes, the cost of the drug is free to both the patients taking part in it, and to the NHS, although NHS trusts must still cover administration costs and provide clinical resources to deliver the EAP.NHS England does not undertake any initiatives to encourage participation in EAPs, which are the responsibility of individual pharmaceutical companies and subject to decision-making by individual NHS trusts.There are no common clinical, data, or regulatory standards for company-sponsored EAPs, meaning each one demands a new protocol to be devised and delivered by each participating trust, which can create significant pressures on clinical and financial resources. Companies providing a sponsored EAP also reserve the right to limit or to close registration of new patients at any time, meaning that any financial and clinical investment made by trusts to establish an EAP could be undermined by a commercial decision that would most likely happen in the event of a negative decision by the National Institute for Health and Care Excellence.NHS England has published guidance for integrated care systems (ICS) on free of charge (FoC) medicine schemes, including EAPs, providing advice on potential financial, resourcing, and clinical risks.ICSs should use the guidance to help determine whether to implement any FoC scheme, including assessing suitability and any risks in the short, medium, and long term. The guidance is available at the following link:https://www.england.nhs.uk/publication/free-of-charge-foc-medicines-schemes-national-policy-recommendations-for-local-systems/

What steps his Department is taking to help improve (a) patient access to and (b) staff retention in NHS dentistry in Leigh and Atherton constituency.

The Government plans to tackle the challenges for patients trying to access National Health Service dental care with a rescue plan to provide 700,000 more urgent dental appointments from April 2025 and recruit new dentists to areas that need them most. To rebuild dentistry in the long term, we will reform the dental contract with the sector, with a shift to focus on prevention and the retention of NHS dentists.The responsibility for commissioning primary care services, including NHS dentistry, to meet the needs of local populations has been delegated to integrated care boards (ICBs) across England. For Leigh and Atherton constituency, the relevant body is NHS Greater Manchester ICB.ICBs have started to recruit posts through the Golden Hello scheme. This recruitment incentive will see up to 240 dentists receiving payments of £20,000 to work in those areas that need them most for three years.

If he will make an assessment of the potential merits of re-evaluating the Units of Dental Activity formula.

To rebuild dentistry in the long term and increase access to National Health Service dental care, we will reform the dental contract, with a shift to focus on prevention and the retention of NHS dentists.There are no perfect payment systems and careful consideration needs to be given to any potential changes to the complex dental system, so that we deliver a system better for patients and the profession.We are continuing to meet with the British Dental Association and other representatives of the dental sector to discuss how we can best deliver our shared ambition to improve access for NHS dental patients.

What progress his Department has made on (a) diagnostics and (b) treatment pathways for people with long covid.

There are no diagnostic tests for long COVID currently approved for use in the United Kingdom, and clinicians must rule out other conditions which present with similar symptoms to diagnose long COVID. Researchers are also working to identify blood-based biomarkers as the basis for diagnostic tests and targets for treatments.Over the last five years, the Government, through the National Institute for Health and Care Research and the Medical Research Council, has invested over £57 million in long COVID research, with almost £40 million of this through two specific research calls on long COVID.This includes clinical trials to test and compare different treatments, and to improve our understanding of long COVID and how health professionals can accurately diagnose the condition. This research has improved the evidence base for clinicians in testing for and treating long COVID.To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID. Further information about the society is available at the following link:https://www.clinicalpcs.org.uk

Whether his Department has plans to help increase dementia diagnosis rates to pre-Covid-19 levels in Leigh and Atherton constituency.

We are committed to recovering the dementia diagnosis rate (DDR) to the national ambition of 66.7%, which in England, at the end of February 2025, was 65.4%.To support recovery of the DDR and implementation of the Dementia Care Pathway, we have developed a dashboard to provide appropriate data and enable targeted support where needed.To reduce variation in diagnosis rates, the Office for Health Improvement and Disparities’ Dementia Intelligence Network has developed a tool for local systems, which includes an assessment of population characteristics such as rurality and socio-economic deprivation. This enables systems to investigate local variation in diagnosis and take informed action to enhance their diagnosis rates. The tool has been released and is available via the NHS Futures Collaboration platform.

What steps his Department is taking with the National Institute for Health and Care Excellence to establish full clinical guidelines for the (a) diagnosis and (b) treatment of people with Tourette's syndrome.

The National Institute for Health and Care Excellence (NICE) has established a prioritisation board that takes decisions on which topics should be prioritised for the development of a clinical guideline, in line with the routing criteria set out in the NICE’s published prioritisation framework, and through engagement with experts and other interested parties. The prioritisation board is currently considering Tourette’s and tic disorders as a possible topic for guideline development, however no final prioritisation decisions have been made yet. The NICE has produced guidance on suspected neurological conditions, which includes recommendations on treatment for tics and involuntary movements in adults and children. The guidance can be found at the following link: https://www.nice.org.uk/guidance/ng127/ The NICE is also developing an Early Value Assessment on digital therapy for chronic tic disorders and Tourette syndrome, and currently expects to publish final guidance in May 2025.

If he will make an assessment of the potential merits of introducing electronic prescriptions for medicinal cannabis.

Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. Electronic prescribing of Schedule 2 and 3 Controlled Drugs in National Health Service primary care settings has been operational since 2019.Electronic prescriptions for controlled drugs in Schedules 2 and 3 must be sent using an advanced electronic signature and sent via the NHS Electronic Prescribing Service as part of enhanced security measures. There are no current plans to make legislative changes to enable similar systems in private healthcare to prescribe Schedule 2 and 3 controlled drugs.

What steps his Department is taking to supporting people with Long Covid in the context of the closure of Long Covid clinics.

Across the National Health Service in England there are services supporting people with post-COVID syndrome, also known as long COVID. These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. Further information can be found on NHS England’s website, at the following link:https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/The commissioning of post-COVID services transitioned from the long COVID national programme to local integrated care boards (ICBs) at the end of March 2024. Funding for post-COVID services in 2024/25 was expected to be allocated based on the previous distribution for 2023/24, to minimise disruption to funding flows and maintain services.NHS England has published commissioning guidance for post-COVID services which sets out the commissioning and service requirements and the oversight of post-COVID services by the ICBs in England for adults, and children and young people (CYP). It outlines the elements that post-COVID services should comprise of and the principles of care for long COVID, and is available at the following link:https://www.england.nhs.uk/long-read/commissioning-guidance-for-post-covid-services-for-adults-children-and-young-people/There is specific advice for general practitioners to manage long COVID. Patients should be managed according to current clinical guidance, such as that published and updated by the National Institute for Health and Care Excellence, the Scottish Intercollegiate Guidelines Network, and the Royal College of General Practitioners, which is available at the following link:https://www.nice.org.uk/guidance/NG188Primary care plays a key role in the long COVID clinical pathway, in considering and excluding potential other causes of symptoms and in determining the appropriate management of symptoms and the timing of onward referral to post-COVID services, if appropriate. A post-COVID-19 syndrome diagnostic pathway, the criteria for referral to post-COVID services, and separate adult and CYP pathways are outlined in the commissioning guidance to help provide consistency of delivery and to improve patient experience.Not all people who report long COVID symptoms will require assessment in a post-COVID assessment service. For example, some of the most common symptoms may still not warrant a specialist assessment as people can benefit from self-management advice, including from the NHS website. Some people may be seen in other disease-specific pathways, depending on their individual circumstances.NHS England has recently completed a long COVID and myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), stocktake, which aimed to provide a nationwide overview of service delivery in commissioning and contracting, assessing access, activity, and outcomes. The findings confirmed widely recognised challenges, specifically significant variation in care delivery across England, and a lack of comprehensive activity data.Executive NHS England board members were updated on the current provision of long COVID and ME/CFS services, noting those challenges. Discussions considered service prioritisation and potential COVID Inquiry recommendations. It was agreed that long COVID and ME/CFS services are rightly commissioned by ICBs, which have responsibility for ensuring coverage for their population.Furthermore, to support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice, to support people affected by long COVID. Further information about the society is available at the following link:https://www.clinicalpcs.org.uk

Pursuant to the Answer of 30 January 2025 to Question 26770 on Chronic Fatigue Syndrome: Health Services, whether the results from the NHS England stocktake will be published.

NHS England’s long COVID and myalgic encephalomyelitis, also known as chronic fatigue syndrome, stocktake aimed to collate information about service commissioning, activity, and delivery, to provide a national overview of the services commissioned by integrated care boards as part of their core activity. The stocktake was completed for an internal NHS England committee and, therefore, there are no plans to publish the findings. However, those findings did confirm the widely recognised challenges of significant variation in care delivery across England, and a lack of comprehensive activity data.

What assessment he has made of the potential impact of the proposed 2025/26 NHS Payment Scheme consultation to enable Integrated Care Boards (ICBs) to set financial limits for each independent provider delivering services under patient right of choice regulations where the level of activity is greater than £0.1 million per year on ADHD waiting times.

A patients’ right to choose is set out in legislation. The proposed 2025/26 NHS Payment Scheme (NHSPS) makes no changes to this right. As required by the Health and Care Act 2022, NHS England has conducted an assessment of the impact of the proposed NHSPS. This is available at the following link: https://www.england.nhs.uk/wp-content/uploads/2025/01/25-26-NHSPS-Consultation-notice-C-impact-assessment.pdfThis impact assessment includes consideration of the impact on patient choice, as well as an assessment of the impact on patients, in line with NHS England’s public sector equality duty.Local integrated care boards (ICBs) are responsible for planning service provision in their local area, including for attention deficit hyperactivity disorder assessments. In doing so, ICBs should take account of waiting lists, and should consider how local funding can be deployed to best meet the needs of their local population.